Alzheimer's disease

Reef Aquarium Market Size Worth $11 Billion By 2028 | CAGR: 10.7%: Grand View Research, Inc.

Retrieved on: 
Tuesday, December 7, 2021

SAN FRANCISCO, Dec. 7, 2021 /PRNewswire/ --The global reef aquarium market size is expected to reach USD 11,020.6 million by 2028, registering a CAGR of 10.7%, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Dec. 7, 2021 /PRNewswire/ --The global reef aquarium market size is expected to reach USD 11,020.6 million by 2028, registering a CAGR of 10.7%, according to a new report by Grand View Research, Inc.
  • Planted tanks and aquascaping are the most popular and developing trends that favor market growth.
  • Constant advancements by companies through technological integration are rapidly transforming the adoption of reef aquariums, which, in turn, drives the market growth.
  • Grand View Research has segmented the global reef aquarium market on the basis of product, end use, and region:
    Reef Aquarium Product Outlook (Revenue, USD Million, 2016 - 2028)

Reef Aquarium Market Size Worth $11 Billion By 2028 | CAGR: 10.7%: Grand View Research, Inc.

Retrieved on: 
Tuesday, December 7, 2021

SAN FRANCISCO, Dec. 7, 2021 /PRNewswire/ --The global reef aquarium market size is expected to reach USD 11,020.6 million by 2028, registering a CAGR of 10.7%, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Dec. 7, 2021 /PRNewswire/ --The global reef aquarium market size is expected to reach USD 11,020.6 million by 2028, registering a CAGR of 10.7%, according to a new report by Grand View Research, Inc.
  • Planted tanks and aquascaping are the most popular and developing trends that favor market growth.
  • Constant advancements by companies through technological integration are rapidly transforming the adoption of reef aquariums, which, in turn, drives the market growth.
  • Grand View Research has segmented the global reef aquarium market on the basis of product, end use, and region:
    Reef Aquarium Product Outlook (Revenue, USD Million, 2016 - 2028)

Todos Medical to Present at Upcoming Emerging Growth Conference

Retrieved on: 
Monday, December 6, 2021

New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be presenting at the upcoming Emerging Growth Conference to be held on December 8, 2021.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical will be presenting at the upcoming Emerging Growth Conference to be held on December 8, 2021.
  • Please register here to ensure you are able to attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1512636&tp_key=b542885e5a&sti... .
  • The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
  • The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.

Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency

Retrieved on: 
Monday, December 6, 2021

SLC13A5-related epilepsy results from a mutation in the SLC13A5 gene that prevents citrate from being taken up into neurons in the brain.

Key Points: 
  • SLC13A5-related epilepsy results from a mutation in the SLC13A5 gene that prevents citrate from being taken up into neurons in the brain.
  • Currently there are no treatments for SLC13A5 deficiency that target the underlying cause of disease.
  • In knockout mouse models of SLC13A5 deficiency, treatment with TSHA-105 resulted in normalized citrate levels, reduced seizure activity and improved survival regardless of age.
  • SLC13A5 deficiency is a form of infantile epilepsy caused by mutations in the SLC13A5 gene.

Sunrise Senior Living Celebrates 40 Years

Retrieved on: 
Monday, December 6, 2021

Today, Sunrise Senior Living marks a special milestone - celebrating 40 years as an industry pioneer and a leading provider of senior communities that provide individualized experiences and best-in-class care.

Key Points: 
  • Today, Sunrise Senior Living marks a special milestone - celebrating 40 years as an industry pioneer and a leading provider of senior communities that provide individualized experiences and best-in-class care.
  • Today, Sunrise is one of the largest senior living providers in the United States and Canada, with the capacity to serve more than 28,000 seniors across 274 communities.
  • Founded in 1981, Sunrise Senior Living is credited with establishing the modern era of senior living.
  • To learn more about Sunrise, please visit www.SunriseSeniorLiving.com or follow us on Facebook , LinkedIn , and Twitter , and The Sunrise Blog .

Global Alzheimer Diagnostic Tests Pipeline Product Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021

The "Alzheimer Diagnostic Tests - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer Diagnostic Tests - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information about the Alzheimer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Alzheimer Diagnostic Tests are tests that detect the disease before it causes the symptoms.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date

New Pilot Study to Examine the Impact of a Therapy Dog Intervention on Loneliness and Related Health Outcomes in Vulnerable Populations

Retrieved on: 
Monday, December 6, 2021

This project, titled "A Pilot Study to Examine the Impact of a Therapy Dog Intervention on Loneliness and Related Health Outcomes in Patients with Mental Illness," aims to address key questions to support an animal-assisted intervention (AAI) as an inpatient intervention for these vulnerable individuals.

Key Points: 
  • This project, titled "A Pilot Study to Examine the Impact of a Therapy Dog Intervention on Loneliness and Related Health Outcomes in Patients with Mental Illness," aims to address key questions to support an animal-assisted intervention (AAI) as an inpatient intervention for these vulnerable individuals.
  • "This study seeks to address this gap and provide further support for animal-assisted intervention for addressing loneliness for this at-risk population."
  • The Consortium is an ongoing, multidisciplinary effort to explore the potential of companion animals to provide effective, complementary treatment for social isolation, loneliness and related health outcomes.
  • Together, HABRI and Mars remain committed to building a strong scientific understanding of the impact of the human-animal bond on populations most vulnerable to loneliness and social isolation.

Insights on the Rat and Mouse Model Global Market to 2028 - by Type, Technology, Service, Application, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021

The outbred model system generated the largest revenue amongst model type as outbred strains are genetically diverse and feature well-characterized, stable genetic variation which accurately reflects the genetic structure of human populations

Key Points: 
  • The outbred model system generated the largest revenue amongst model type as outbred strains are genetically diverse and feature well-characterized, stable genetic variation which accurately reflects the genetic structure of human populations
    Therefore, outbred strains such as the Diversity Outbred (DO) mice are used to analyze the genetic complexity behind cancer, autoimmune disorders, addiction, obesity, heart disease, diabetes, and Alzheimer's disease
    Cancer is the largest revenue-generating application segment as the mouse and human genomes are homologous.
  • Thus, it provides a good tool for cancer research as well as for drug discovery
    Pharmaceutical and biotechnology companies dominated the end-use segment in terms of revenue share in 2020.
  • Rat and mice models are some of the most used animal models in drug discovery
    Genetically engineered models play a vital role to assess and characterize target identification, disease pathology, and in vivo assessment of new molecular entities
    5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    6.1 Recent Developments & Impact Analysis, by Key Market Participants

Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

Retrieved on: 
Monday, December 6, 2021

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.
  • We are encouraged by the data thus far and confident in our progress towards developing a safe and effective treatment for this underserved population.
  • ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.
  • This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Cowen Research Identifies Themes That Will Define Industries and Drive Investment Performance In 2022

Retrieved on: 
Monday, December 6, 2021

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (Cowen or the Company), today announced the release of Themes 2022.

Key Points: 
  • NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (Cowen or the Company), today announced the release of Themes 2022.
  • This annual handbook identifies themes in which Cowens sector knowledge and collaborative approach provide integral insight into trends, policies and advancements that are defining or redefining industries.
  • Bill Bird, Cowens Head of Thematic Content, said, The fundamental viewpoints featured in Themes 2022 are bolstered by the insights of our Washington Research Group.
  • Cowen Inc. (Cowen or the Company) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division.